The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / Is It Rejection – or Something Else?
Histology Molecular Pathology Biochemistry and molecular biology Clinical care

Is It Rejection – or Something Else?

Combining molecular, histologic, and laboratory findings may support more individualized transplant care

By Jessica Allerton 11/17/2026 Interview 4 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

Objective:

The article examines the objective, findings, and clinical context described in Is It Rejection – or Something Else?.

Approach:
  • Testing methods: Biopsy-based molecular tests measure gene expression in tissue; other assays examine blood or urine for patterns associated with rejection or injury.
  • Example: MMDx Kidney uses microarray gene-expression measurements and an organ-specific reference dataset to estimate the probability of molecular patterns associated with rejection or injury.
Key Findings:
  • Biopsy and histology remain central, but biopsies sample only a small part of the organ and some findings can be difficult to interpret consistently.
  • Creatinine and estimated glomerular filtration rate indicate kidney function but do not identify why it has changed.
  • Molecular patterns may provide additional information when microscopic changes are subtle, but they do not always establish the cause of injury.
  • Rejection, infection, medication toxicity, reduced blood flow, obstruction, and recurrence of the original disease can cause graft dysfunction and may require different management.
  • Donor-specific antibodies indicate an immune response associated with increased risk but do not alone confirm active rejection.
  • Blood- and urine-based biomarkers are under investigation; current evidence does not support their universal use as replacements for biopsy.
Interpretation:

Molecular testing can add information about biological activity in sampled tissue and may help narrow possible causes of graft injury. Its role in guiding treatment or medication dosing is still being established.

Limitations:
  • Biopsy sampling covers only a small portion of the kidney and molecular analysis cannot map the entire organ.
  • Histology is an imperfect reference standard; interpretations can vary, and some findings occur in multiple conditions.
  • A molecular test trained to reproduce histologic diagnoses may inherit limitations of those diagnoses.
  • Diagnostic accuracy and clinical benefit are separate questions; test performance should be assessed in independent samples and, ideally, prospective studies.
  • No single test result provides a definitive answer.
Conclusion:

The article presents molecular testing as complementary to biopsy, routine laboratory tests, and clinical assessment. It notes that further evidence is needed to establish how molecular and less invasive biomarker tests should guide clinical decisions.

Sources:
  • Article context provided by the user

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.